Document:

<PAGE>

                                                           EXHIBIT 10.93

* CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                   AMENDMENT NO. 4 TO ENBREL SUPPLY AGREEMENT

         THIS AMENDMENT NO. 4 TO ENBREL SUPPLY AGREEMENT (this "Amendment") is
effective as of October 31, 2003 between and among Genentech Inc., a Delaware
corporation ("Genentech"), and Immunex Corporation, a Washington corporation and
a wholly owned subsidiary of Amgen Inc. ("Immunex") (collectively the
"Parties").

         Genentech and Immunex are parties to that certain Enbrel Supply
Agreement dated April 12, 2002, as amended by that certain Amendment No. 1 to
Enbrel Supply Agreement dated September 20, 2002, that certain Amendment No. 2
dated July 16, 2002 and that certain Amendment No. 3 to Enbrel Supply Agreement
dated March 26, 2003 (as amended, the "Agreement").

         WHEREAS Genentech had initially provided Immunex with a forecast which
provided that [*];

         WHEREAS Immunex requested that [*];

         WHEREAS Genentech has agreed to [*];

         WHEREAS in order to accommodate Immunex's request for [*], Genentech
has had to [*];

         WHEREAS the Parties are agreeable to [*];

         WHEREAS the Parties are agreeable to [*].

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows:

         1. Exhibit A to the Enbrel Supply Agreement is deleted in its entirety
and replaced with the following:

* Confidential Treatment Requested.

<PAGE>

<TABLE>
<CAPTION>
Calendar Year                Minimum Runs*              Maximum Runs*
-------------                -------------              -------------
<S>                          <C>                        <C>
     [*]                          [*]                        [*]
     [*]                          [*]                        [*]
     [*]                          [*]                        [*]
</TABLE>

*  When used in this Exhibit, the term "Runs" is a defined term, and it shall
have the meaning given in the Agreement.

** The foregoing is not intended to relieve Amgen from payment obligations for
Runs commenced prior to November 1, 2003 provided that all applicable conditions
for payment set forth in the Agreement have been satisfied.

***[*].

         2. Immunex represents and warrants that it has the corporate power and
authority and consents and the legal right to enter into this Amendment and has
taken all necessary corporate action on its part to authorize execution of this
Amendment.

         3. All capitalized terms not defined herein shall have the meaning set
forth in the Agreement.

         4. Except as set forth herein, all other terms of the Agreement remain
in full force and effect.

         5. This Amendment may be executed in counterparts, each of which shall
be deemed an original, and all of which, taken together, shall constitute one
and the same instrument. This Amendment shall be effective upon full execution
by facsimile or original, and a facsimile signature shall be deemed to be and
shall be as effective as an original signature. This Amendment may not be
amended except by a written instrument duly executed and delivered by the
Parties.

         IN WITNESS WHEREOF, the Parties hereto have executed this Amendment
effective as of the date set forth above.

GENENTECH INC.                                IMMUNEX CORPORATION

By:  /s/ David Ebersman                       By:  /s/ Efi Cohen-Arazi
   ------------------------------------           ------------------------------

Name: David Ebersman                          Name: Efi Cohen-Arazi

Title: Sr. Vice President of Product          Title: VP Corporate Manufacturing
       Operations

Date:  12/24/03                               Date: 12/19/03

* Confidential Treatment Requested.<PAGE>
* CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                                                   EXHIBIT 10.94

                                 DESCRIPTION OF

                               AMENDMENT NO. 1 TO

                    AMENDED AND RESTATED PROMOTION AGREEMENT

        The following is a description of Amendment No. 1 to the Amended and
Restated Promotion Agreement, dated as of December 16, 2001, by and among Wyeth,
a Delaware corporation (formerly American Home Products Corporation, "Wyeth"),
Amgen Inc., a Delaware corporation ("Amgen"), and Immunex Corporation, a
Washington corporation and wholly-owned subsidiary of Amgen ("Immunex") (the
"Promotion Agreement"). For purposes of the Amendment, all capitalized terms
used but not otherwise defined in the Amendment shall have the meanings assigned
to them in the Promotion Agreement. The Amendment is effective as of July 8,
2003. The Amendment is limited and does not constitute a modification,
acceptance or waiver of any other provision of the Promotion Agreement.

Wyeth, Amgen, and Immunex amended the Promotion Agreement by inserting the
following provision as a new Section 6.1(e):

"6.1(e) Additional Spending. Notwithstanding anything to the contrary in this
Agreement, the Parties approve $[*] (U.S. Dollars) in spending in 2003 for
promotion, sales and marketing activities and for the medical affairs studies
specified in Section 3.06A of the TNFR Agreement, which spending shall be in
addition to any expenses for promotion, marketing, selling and/or medical
affairs studies already agreed to by the Parties for 2003 prior to July 8, 2003.
The EMC shall be responsible for determining the activities to be funded with
the additional $[*], subject to Section 3.06A of the TNFR Agreement which
earmarks a portion of the additional $[*] for certain [*]. If the [*] of
Released Drug Product (as defined in the Collaboration and Global Supply
Agreement effective as of November 6, 2001 between Immunex and Wyeth, as amended
by Amendment No. 1 thereto dated July 8, 2003 (the "CGSA")) [*] to [*] in [*]
pursuant to Sections 5.1B(a) and 5.1B(b) of the CGSA (including Product [*] the
[*] (each as defined in the CGSA) [*] in [*] pursuant to Section 5.1B(a) and
5.1B(b) of the CGSA, as set forth in Section 5.1B(d) of the CGSA) does not equal
or exceed [*] in the [*], all of the [*] for such additional [*] shall be borne
by [*]. If the [*] of Released Drug Product [*] to [*] in [*] pursuant to
Section 5.1B(a) and 5.1B(b) of the CGSA (including Product [*] the [*] (each as
defined in the CGSA) [*] in [*] pursuant to Sections 5.1B(a) and 5.1B(b) of the
CGSA, as set forth in Section 5.1B(d) of the CGSA) equals or exceeds [*] in the
[*], all of the [*] for such additional [*] shall be [*] between [*]."

The Amendment was executed by the following duly authorized parties.

WYETH

/s/ Robert Repella
-----------------------------------
By: Robert Repella
Title: VP, Global Business Manager

<PAGE>

* CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

IMMUNEX CORPORATION

/s/ Richard Nanula
-----------------------------------
By: Richard D. Nanula
Title: Chief Financial Officer

WYETH

/s/ Richard Nanula
-----------------------------------
By: Richard D. Nanula
Title: Executive Vice President, Finance,
       Strategy and Communications, and
       Chief Financial Officer<PAGE>

                                                                   EXHIBIT 10.95

February 11, 2004

David Scott
Elk Horn Lodge #310
51 Offerson Road
Beaver Creek, CO  81620

Dear David:

AMENDMENT AND RESTATEMENT OF DECEMBER 22, 2003 LETTER

The following is our letter agreement dated December 22, 2003 (the "Original
Letter"), which has been amended and restated to clarify and reflect our
subsequent discussions and correspondence on certain points that were not
reflected in the Original Letter. As so amended and restated, this letter
supersedes the Original Letter and shall be effective as of December 26, 2003,
the date that you signed the Original Letter. There is no need for you to
re-sign your Proprietary Information and Inventions Agreement and your Mutual
Agreement to Arbitrate Claims that were attached as Attachment 1 to the Original
Letter, which agreements you signed on December 26, 2003 because we have made no
changes to those agreements. Accordingly, those agreements continue to be in
full force and effect. In addition, there is no need for you to resign the
employment application that was enclosed with your original letter.

On behalf of Kevin Sharer (the "CEO"), I am pleased to convey to you the offer
of the position of Senior Vice President, General Counsel, and Corporate
Secretary, based at our Thousand Oaks headquarters. This position reports
directly to the CEO. This offer has been reviewed and approved through unanimous
written consent by Amgen's Compensation and Management Development Committee.

Your monthly salary will be $45,833.33 (~ $550,000 annually), and you will first
be eligible to be considered for an annual merit increase in March 2005 as part
of the annual performance review process.

As a Senior Vice President and member of Amgen's Executive Committee, you will
be eligible to participate in Amgen's Executive Incentive Plan (the "EIP")
pursuant to the terms of the EIP. Your annual target incentive opportunity will
be 65% of your base salary earnings during the year. Your actual EIP bonus for
any performance year may be more or less than this target amount and may vary
based on Corporate and Functional Unit performance as well as management's
assessment of your individual performance and contribution. However, in order to
ease your transition to a new company, Amgen

                                                                               1
<PAGE>

will guarantee a minimum incentive payment of $500,000 (payable in March 2005)
for the 2004 performance year, or the actual results from the EIP, whichever is
higher. You must be actively employed by Amgen on December 31, 2004 to receive
the guaranteed payment for 2004.

In addition, you will be entitled to a $500,000 bonus, which (less federal,
state and local tax deductions and other applicable withholdings) will be paid
within 30 days of your start date. If you are not still employed by Amgen as of
the date the bonus is paid, the bonus will not be considered earned or vested
and will not be prorated.

You will be granted an option to purchase 100,000 shares of Amgen's common stock
at a price equal to 100% of the fair market value on your start date. This
option shall be an Incentive Stock Option ("ISO") to the extent permitted by
regulation and the remaining option shares of the grant shall be non-qualified
stock options. This option shall be vested at a rate of 25% per year for four
years, beginning one year from the date of grant, and the option will expire
seven years from the date of grant.

Provided you begin employment at Amgen prior to March 1, 2004, you will be
eligible to participate in the 2004 Amgen Long-Term Performance Incentive
Program; should you begin employment with Amgen after February 29, 2004, you
will be eligible to participate in the Amgen Long-Term Performance Incentive
Program beginning in 2005. Grants under this program are discretionary and are
subject to approval by Amgen's Compensation and Management Development Committee
(the "Committee"). Subject to the approval of the Committee and your start date,
your 2004 grant under this program will be the equivalent of 100,000 stock
options. It is anticipated that the grant will be delivered as a combination of
stock options (50,000) and performance units (25,000), during March 2004.

Amgen will award you 25,000 shares of restricted stock under Amgen's Amended and
Restated 1991 Equity Incentive Plan on your start date, in consideration of your
payment of the $.0001 per share par value of the restricted shares (the "Par
Value Price"), in the aggregate amount of $2.50. This grant is being made for
retention purposes and to tie your financial success to the financial success of
our shareholders.

This grant of restricted stock will vest as follows, contingent upon your being
actively employed with Amgen through each vesting date:

<TABLE>
<S>                                                  <C>
The first anniversary of your start date             6,250 shares
The second anniversary of your start date            6,250 shares
The third anniversary of your start date             6,250 shares
The fourth anniversary of your start date            6,250 shares
</TABLE>

Upon the termination of your active employment with Amgen, any unvested shares
of restricted stock will be forfeited, except that upon termination of your
employment due to your "Permanent and Total Disability," as defined below, or
your death, then the vesting of the unvested shares of restricted stock will be
accelerated so that all the restricted stock will be fully vested as of the date
of termination. For the purposes of this provision, you

                                                                               2
<PAGE>

shall have incurred a "Permanent and Total Disability" when such a disability
has been certified by the Social Security Administration prior to the date of
termination. Amgen will hold the certificates representing any unvested shares
of restricted stock until the shares vest, at which time Amgen will issue you a
certificate representing the vested shares. Upon the forfeiture of any of the
restricted shares, Amgen will pay you an amount equal to the par value price for
each forfeited share.

As an Executive Incentive Plan participant, you are also eligible to participate
in the Amgen Nonqualified Deferred Compensation Plan (the "DCP") to voluntarily
defer, on a pre-tax basis, a portion of your annual earnings, including base
salary and EIP payments. Upon receipt of your acceptance of employment at Amgen,
you will be contacted directly by a member of the Amgen Executive Compensation
Group to provide you with further details of the DCP and, if you wish, to
arrange for your enrollment in the plan. For this enrollment, which must be
completed within 30 days of the first date of your employment with Amgen, you
may elect to defer up to 50% of your 2004 base salary and up to 80% of your 2004
EIP bonus to be paid in 2005.

If, within the first two years of your employment with Amgen, either: (i) Amgen
terminates your employment without Cause, as defined below, or (ii) you resign
your employment due to a reduction of your duties or your base salary or annual
target incentive opportunity under the EIP, then you will be entitled to three
years of base salary and target incentive paid monthly plus continued health
care coverage that will run concurrent with coverage mandated under the
Consolidated Omnibus Budget Reconciliation Act of 1985 for three years following
the date of termination unless coverage is obtained from another employer, but
only if you sign a general release form furnished to you by Amgen. If you intend
to resign your employment for reduction of duties or compensation, you must
notify the Company in writing. If Amgen fails to cure or remedy your reason for
resignation within thirty (30) days of its receipt of your notification and you
still choose to resign, you must do so within fifteen (15) days of Amgen's
failure to cure or remedy your reason.

As a Senior Vice President at Amgen, you will also be a participant in the Amgen
Inc. Change of Control Plan. If upon termination you are also entitled to
receive severance benefits under the Amgen Inc. Change of Control Severance Plan
(the "COC Plan") on account of a termination covered by this provision, you will
be paid the greater of the amount provided above or provided in the COC Plan,
but not both amounts.

                                                                               3
<PAGE>

For the purpose of the above two provisions, "Cause" means (i) your conviction
of a felony, (ii) the engaging by you in conduct that constitutes willful gross
neglect or willful gross misconduct in carrying out your duties to Amgen,
resulting, in either case, in material economic harm to Amgen, unless you
believed in good faith that such conduct was in, or not contrary to, the best
interests of Amgen, (iii) your material breach of any of the terms of this
letter agreement or the Proprietary Information and Inventions Agreement or (iv)
your failure to follow any lawful directive given by me with respect to your
employment. For purposes hereof, no act, or failure to act, on your part shall
be deemed "willful" unless done, or omitted to be done, by you not in good
faith.

You will also have the opportunity to participate in our comprehensive benefits
program. Amgen's excellent health care plan currently includes medical, dental,
and vision coverage for you and your eligible dependents. Amgen currently pays
the majority of the costs associated with these programs while staff members
share through payroll deductions. Please be advised that in order for you and
your dependents to be eligible to participate in Amgen's health care plan you
must:

         1.       Report to work at Amgen or another location to which you are
                  required to travel and perform the regular duties of your
                  employment.

         2.       Contact the Amgen Benefit Center at Fidelity, 1-877-999-7779,
                  to enroll within 31 days of your hire date.

         3.       Meet all other eligibility requirements under the plan.

Amgen's Retirement & Savings 401(k) Plan provides an opportunity for staff
members to elect to defer eligible earnings up to the federal annual
contribution limit on a tax-deferred basis. Amgen will also contribute to your
401(k) account to help you save for your future financial goals. The benefits,
services and programs offered are summarized in the enclosed brochure called
"Welcome to Amgen - Total Compensation and Benefits at Amgen."

You are eligible to participate in Amgen's relocation program. A summary of the
program is attached as part of this offer (Attachment 2). As stated in the
summary, Amgen will cover up to 180 days of temporary executive housing at your
new location should you require such support.

REQUIRED DOCUMENTS

Enclosed and included as part of this offer (Attachment 1) is information
regarding Amgen's Proprietary Information and Inventions Agreement, the
Immigration Reform & Control Act, and a packet of materials entitled
"Arbitration of Disputes - Amgen Inc." which includes a Mutual Agreement to
Arbitrate Claims. This offer is contingent upon your completing the items
described in Attachment 1.

Also enclosed is an application for employment, which is a required document for
the successful completion of our staffing process. If you have not completed
this document

                                                                               4
<PAGE>

as part of the search process, please do so at this time and return it with all
other required documents.

EMPLOYMENT AT WILL

By signing this letter, you understand and agree that your employment with Amgen
is at-will. Therefore, your employment can terminate, with or without Cause, and
with or without notice, at any time, at your option or Amgen's option, and Amgen
can terminate or change all other terms and conditions of your employment, with
or without Cause, and with or without notice, at any time. This at-will
relationship will remain in effect throughout your employment with Amgen Inc. or
any of its subsidiaries, or affiliates. This letter constitutes the entire
agreement, arrangement and understanding between you and Amgen on the nature and
terms of your employment with Amgen. This letter supersedes any prior or
contemporaneous agreement, arrangement or understanding on this subject matter.
By executing this letter as provided below, you expressly acknowledge the
termination of any such prior agreement, arrangement or understanding. Also, by
your execution of this letter, you affirm that no one has made any written or
verbal statement that contradicts the provisions of this letter. The at-will
nature of your employment, as set forth in this paragraph, can be modified only
by a written agreement signed by both Amgen's CEO and you which expressly alters
it. This at-will relationship may not be modified by any oral or implied
agreement, or by any Company policies, practices or patterns of conduct.

Congratulations! Kevin has asked me to convey that he is very excited about the
contribution that you will make to Amgen's success through your leadership of
our Legal function as well as the corporate leadership you will provide as a
member of the Executive Committee. He also believes that Amgen will provide you
with attractive opportunities for personal achievement and growth. If you accept
our offer, please sign and date the copy and return it in the enclosed envelope.
Please retain the original offer letter for your records. If you have any
questions regarding this offer, please contact me at (805) 447-8912 or Steven
Wecker at (805) 447-7093.

Sincerely,

Chip Bell
Senior Director
Compensation and Benefits

CB/sw

Enclosures

                                                                               5
<PAGE>

_________________________________________

Signature of Acceptance              Date

Anticipated Start Date: February 23, 2004

                                                                               6
<PAGE>

                                  ATTACHMENT 1

In order to accept our offer you will be required to:

         A)       Complete, date and sign the Amgen Proprietary Information and
                  Inventions Agreement and return it with your signed offer
                  letter.

         B)       Date and sign the enclosed Mutual Agreement to Arbitrate
                  Claims and return it with your signed offer letter.

         C)       You will be required to provide Amgen with proof of your
                  identity and eligibility for employment per requirements of
                  the Immigration Reform and Control Act of 1986 within 3
                  (three) days of hire. Information pertaining to this Act and
                  required proof are enclosed.

                                                                               7
<PAGE>

                                  ATTACHMENT 2

RELOCATION ASSISTANCE COVERAGE

All relocation expense coverage to be provided as a part of your Amgen
employment offer is outlined in this attachment. This relocation expense
coverage is designed to offset most of the cost of your relocation. However, as
a new staff member, it is expected that you will make every effort to reduce or
eliminate relocation expense wherever possible. Relocation benefits are limited
to one benefits package per household.

PLEASE NOTE:
Amgen has engaged the services of Primacy Relocation ("Primacy") to provide
relocation services to our relocating staff members. Once we have received your
signed acceptance of this offer, we will authorize a Primacy Relocation
Consultant to contact you to initiate your relocation benefits.

The following relocation benefits will be coordinated and/or delivered by
Primacy Relocation:

HOUSE HUNTING TRIP

To assist you with your house hunting efforts, Amgen will provide a 5-day trip
for you and your household members. Coordinated through World Travel and
according to Corporate Travel Policy, Amgen will cover the cost of round-trip
airfare, ground transportation and hotel (room & tax only). Please contact World
Travel (866) 613-2205 to make your reservations at least 7 days prior to your
planned trip. In addition, Amgen will provide a per diem allowance for up to 5
days, to help offset the cost of food and miscellaneous items during the
house-hunting trip. The per diem allowance should be requested and will be paid
at the same time as the incidental lump sum allowance.

MARKETING ASSISTANCE AND HOME SALE PROGRAM

A Marketing Assistance Program is available to assist in the sale of your
current primary residence. Also, through the Home Sale Program, we will offer
you the opportunity for a third party purchase of your current primary residence
if you are unable to sell your home within 90 days. Amgen will pay the seller's
normal, non-recurring closing costs associated with the sale of your home (i.e.,
real estate commission, title expense, etc.). YOU MUST SPEAK TO A PRIMACY
RELOCATION CONSULTANT BEFORE TAKING ANY ACTION TO SELL YOUR HOME.

Additionally, if you have your home listed, are actively participating in the
Home Marketing Assistance program and are closing escrow on the purchase of a
home in the new "local area" prior to the sale of your current residence, Amgen
will reimburse up to 3

                                                                               8
<PAGE>

months of your current mortgage payment and other reasonable related costs
(i.e., utilities, prorated taxes, insurance, etc.).

Homes excluded from eligibility may include but are not limited to: cooperative
apartments, mobile homes, homes with more than two units, vacation or second
homes, homes with excessive acreage, investment properties, homes with
unmarketable titles, homes with E.I.F.S. (synthetic stucco) siding, homes with a
history of water related or structural problems, or homes where environmental
problems (i.e. underground fuel storage tanks, radon, asbestos) exist.

TEMPORARY LIVING EXPENSES

Temporary living expenses will be covered for a period of up to 180 days in
Amgen leased executive lodging units. If you need to stay in the temporary
lodging unit more than 180 days, you will be responsible for the cost of the
unit at the daily rate negotiated by Amgen. Since Amgen has contracted for these
temporary lodging accommodations, there is no need to make arrangements on your
own.

ONE-WAY TRAVEL EXPENSES

Amgen will reimburse one-way travel expenses for you and your household members
to take residence in the "local area." Amgen will provide a rental car for your
use for a maximum of 14 days. This car may only be operated by you and your
spouse, and may only be operated in the local area. Local area shall be defined
as no more than 75 miles from your place of work. Amgen will not be responsible
for, and will not cover, any damage or injuries resulting from the operation of
the vehicle outside of these parameters. Additionally, if you are not yet an
employee of Amgen when you operate the vehicle, you must accept the insurance
provided through the rental agency. You should contact World Travel (866)
613-2205 to make your travel reservations.

MOVING HOUSEHOLD GOODS

Amgen will arrange for packing, moving, and unpacking of normal household
possessions, including up to two automobiles. Amgen will also pay for up to 180
days storage of household goods, if necessary. Amgen will assist you with
expenses relating to the transport of small pets such as cats and dogs. However,
Amgen will not transport, and does not recommend transporting, large animals
such as horses. Reimbursement of expenses (transporting pets to new location) is
not to exceed $500 per household. Please note that pets are shipped at your own
risk; Amgen will not be responsible for your pet's health while in transit.

                                                                               9
<PAGE>

LUMP SUM ALLOWANCE

Amgen will provide you with a $3,000.00 lump sum to be used at your discretion,
to cover incidental expenses associated with your move that are not covered in
other sections of relocation coverage. Receipts or other accounting for the use
of this allowance are not required.

RENTAL ASSISTANCE - SECURITY DEPOSIT NEW RESIDENCE

Amgen will reimburse you for the deposit on a rental property in the new "local
area" in an amount not to exceed the equivalent of one month's rent.

OR

NON-RECURRING HOME PURCHASE CLOSING COSTS

Amgen will reimburse loan origination fees of up to 1% of the mortgage amount
and loan discount points according to the sliding scale below, which is governed
by current mortgage market conditions.

The sliding scale for loan discount points is based upon the prevailing 30/year
60/day Yield as set by the Federal National Mortgage Association (the "FNMA"),
and as published in the "Money Rates" section of the Wall Street Journal on the
day you lock-in your mortgage interest rate. The following sliding scale
applies:

          - If the FNMA index is 8% or less, 0 discount points will be
          reimbursed;

          - If the FNMA index is at least 8.01% but not more than 8.49%, up to
          0.5 points will be reimbursed;

          - If the FNMA index is at least 8.5% but not more than 8.99%, up to
          1.0 point will be reimbursed;

          - If the FNMA index is at least 9% but not more than 9.99%, up to 1.5
          points will be reimbursed; and

          - If the FNMA index is 10% or higher, up to 2 points will be
          reimbursed.

          (the up to 1% loan origination fee reimbursement occurs regardless of
          the FNMA index; scale applies only to loan discount point
          reimbursement)

In addition, you will be reimbursed for other Lender's fees, including but not
limited to fees for the appraisal, credit report, tax service fees, processing
fees, flood zone determination fees, underwriting fees, warehouse fees, rate
lock-in fees, broker fees, lender document preparation fees, commitment fees,
lender courier fees, escrow waiver fees, and loan review fees, in an amount not
to exceed Six Hundred Fifty and No/Dollars ($650.00). You will also be
reimbursed for the customary non-recurring buyer's closing costs for Escrow
and/or Title fees.

                                                                              10
<PAGE>

TAX GROSS-UP ASSISTANCE

Amgen will provide for tax assistance (gross-up) for the non-deductible portion
of those reimbursed relocation expenses, which are considered as ordinary income
for state or federal income tax purposes.

LOCAL AREA

References to the "local area" generally means the new work site is a minimum of
50 miles from the staff member's current residence, and the move to the new
residence reduces commuting time by at least 50%.

DURATION OF RELOCATION

This relocation expense coverage is intended to assist in getting you
established in your new residence in the "local area" as quickly as possible.
Therefore, it is required that all relocation assistance provided for in this
attachment and all expense reimbursements for this assistance be completed
within one year from your date of hire.

                                       11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]